Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cardiovascular pathology

• Publication date

  2011-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.carpath.2010.03.007PMID 20434371PMCID PMC3159956
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extracellular matrix remodeling during the progression of volume overload-induced heart failure.

  2010cited by this paper
• Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction.

  2009cited by this paper
• Protective Effects of PARP-1 Knockout on Dyslipidemia-Induced Autonomic and Vascular Dysfunction in ApoE−/− Mice: Effects on eNOS and Oxidative Stress

  2009cited by this paper
• PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.

  2009cited by this paper
• Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability.

  2008cited by this paper
• Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality

  2008cited by this paper
• Effect of L-2286, a Poly(ADP-ribose)polymerase Inhibitor and Enalapril on Myocardial Remodeling and Heart Failure

  2008cited by this paper
• Angiotensin II Regulates Cardiac Hypertrophy via Oxidative Stress but Not Antioxidant Enzyme Activities in Experimental Renovascular Hypertension

  2008cited by this paper
• Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.

  2007cited by this paper
• TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways.

  2007cited by this paper
• Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy?

  2007cited by this paper
• Abstract 1131: PARP1 is required for Adhesion Molecule Expression in Atherogenesis

  2007cited by this paper
• Poly(ADP-Ribose) Polymerase Inhibition Reduces Atherosclerotic Plaque Size and Promotes Factors of Plaque Stability in Apolipoprotein E–Deficient Mice: Effects on Macrophage Recruitment, Nuclear Factor-&kgr;B Nuclear Translocation, and Foam Cell Death

  2007cited by this paper
• Angiotensin II Receptor Blocker Reduces Oxidative Stress and Attenuates Hypoxia-Induced Left Ventricular Remodeling in Apolipoprotein E–Knockout Mice

  2007cited by this paper
• Cardiac Hypertrophy: Mechanisms and Therapeutic Opportunities

  2007cited by this paper
• High-Density Lipoprotein Cholesterol and Insulin Resistance Are Independent and Additive Markers of Left Ventricular Hypertrophy in Essential Hypertension

  2007cited by this paper
• Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

  2007cited by this paper
• Matrix metalloproteinases (MMPs) in health and disease: an overview.

  2006cited by this paper
• Hipertrofia cardiaca: eventos moleculares y celulares

  2006cited by this paper
• Mast Cell Contributes to Cardiomyocyte Apoptosis after Coronary Microembolization

  2006cited by this paper
• Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy.

  2006cited by this paper
• Structure and function of matrix metalloproteinases and TIMPs.

  2006cited by this paper
• Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy.

  2006cited by this paper
• [Cardiac hypertrophy: molecular and cellular events].

  2006cited by this paper
• Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease

  2006cited by this paper
• Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload.

  2006cited by this paper
• Shock, inflammation and PARP.

  2005cited by this paper
• Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice.

  2005cited by this paper
• Serum lipid levels and factors affecting atherogenic index in Japanese children.

  2005cited by this paper
• Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture.

  2005cited by this paper
• TIMP-2: an endogenous inhibitor of angiogenesis.

  2005cited by this paper
• Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target.

  2004cited by this paper
• Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment

  2003cited by this paper
• TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.

  2003cited by this paper
• Cardiac mast cell-mediated activation of gelatinase and alteration of ventricular diastolic function.

  2002cited by this paper
• Matrix metalloproteinases and atherosclerotic plaque instability

  2002cited by this paper
• Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity.

  2002cited by this paper
• NF-Y and Sp1 Cooperate for the Transcriptional Activation and cAMP Response of Human Tissue Inhibitor of Metalloproteinases-2*

  2000cited by this paper
• Hemodynamic changes in apolipoprotein E-knockout mice.

  2000cited by this paper
• HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte.

  1998cited by this paper
• Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet.

  1998cited by this paper
• Structure and Characterization of the Human Tissue Inhibitor of Metalloproteinases-2 Gene*

  1996cited by this paper

• Cellular and Molecular Mechanisms of Mast Cells in Atherosclerotic Plaque Progression and Destabilization

  2024cites this paper
• Mast Cells in Cardiac Remodeling: Focus on the Right Ventricle

  2024cites this paper
• Targeting DNA damage response in cardiovascular diseases: from pathophysiology to therapeutic implications.

  2022cites this paper
• Differential effects of poly(ADP ribose) polymerase inhibitor-based metronomic therapy on programmed death-ligand 1 and matrix-associated factors in human myeloid cells.

  2022cites this paper
• PARPs in lipid metabolism and related diseases.

  2021cites this paper
• Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease.

  2020cites this paper
• Analysis of mast cells and myocardial fibrosis in autopsied patients with hypertensive heart disease.

  2020cites this paper
• The impact of PARPs and ADP-ribosylation on inflammation and host–pathogen interactions

  2020cites this paper
• PARP-1 inhibition provides protection against elastase-induced emphysema by mitigating the expression of matrix metalloproteinases

  2019cites this paper
• Morphological and histopathological evaluation of autopsied patients with hypertensive cardiopathy.

  2019cites this paper
• Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders

  2018cites this paper
• Critical analysis of aortic dysmorphism in Marfan Syndrome

  2017cites this paper
• PARP activity and inhibition in fetal and adult oligodendrocyte precursor cells: Effect on cell survival and differentiation.

  2017cites this paper
• Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition.

  2017cites this paper
• Studies on the role of GPR55 in cardiovascular physiology and pathophysiology

  2017cites this paper
• PARP-1 depletion in combination with carbon ion exposure significantly reduces MMPs activity and overall increases TIMPs expression in cultured HeLa cells

  2016cites this paper
• Poly (ADP-ribose) polymerase-1: an emerging target in right ventricle dysfunction associated with pulmonary hypertension.

  2015cites this paper
• Inhibition of Poly-(ADP-Ribose) Polymerase Protects the Kidney in a Canine Model of Endotoxic Shock

  2015cites this paper
• Poly(ADP‐ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications

  2014cites this paper
• The analysis of functional modules in primary cardiomyopathies

  2014cites this paper
• Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation

  2014cites this paper
• Poly(ADP-ribosyl)ation in carcinogenesis.

  2013cites this paper
• Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases.

  2011cites this paper